Additionally, the 36-month beta value for ACRS is 0.14. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 4 rating it as “overweight,” 7 rating it as “hold,” and 0 rating it as “sell.”
The public float for ACRS is 67.57M and currently, short sellers hold a 3.57% ratio of that float. The average trading volume of ACRS on November 18, 2024 was 560.23K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ACRS) stock’s latest price update
Aclaris Therapeutics Inc (NASDAQ: ACRS)’s stock price has soared by 24.39 in relation to previous closing price of 2.05. Nevertheless, the company has seen a loss of -3.04% in its stock price over the last five trading days. prnewswire.com reported 2024-11-18 that Biosion receives over $40 million cash payment as upfront license fee and reimbursement for certain development costs & drug product materials, and 19.9% shares of common stock of Aclaris Therapeutics; additional regulatory and sales milestone payments exceed $900M with tiered single digit sales royalty Aclaris Therapeutics will be responsible for development and commercialization of BSI-045B, a novel anti-TSLP monoclonal antibody, and BSI-502, a novel bispecific antibody that is directed against both TSLP and IL4R worldwide (excluding Greater China) NEWARK, Del. and NANJING, China, Nov. 18, 2024 /PRNewswire/ — Biosion, Inc. (Biosion), a global R&D stage biotechnology company, today announced that it has entered into an exclusive license agreement with Aclaris Therapeutics (NASDAQ: ACRS) for worldwide rights (excluding Greater China) to BSI-045B, a potential First-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-clinical stage, novel bispecific antibody that is directed against both TSLP and IL4R.
ACRS’s Market Performance
Aclaris Therapeutics Inc (ACRS) has experienced a -3.04% fall in stock performance for the past week, with a 114.29% rise in the past month, and a 104.00% rise in the past quarter. The volatility ratio for the week is 15.39%, and the volatility levels for the past 30 days are at 11.49% for ACRS. The simple moving average for the past 20 days is 25.37% for ACRS’s stock, with a 98.47% simple moving average for the past 200 days.
Analysts’ Opinion of ACRS
Evercore ISI gave a rating of “Outperform” to ACRS, setting the target price at $22 in the report published on October 03rd of the previous year.
ACRS Trading at 68.05% from the 50-Day Moving Average
After a stumble in the market that brought ACRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.25% of loss for the given period.
Volatility was left at 11.49%, however, over the last 30 days, the volatility rate increased by 15.39%, as shares surge +109.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +115.25% upper at present.
During the last 5 trading sessions, ACRS fell by -3.42%, which changed the moving average for the period of 200-days by +109.92% in comparison to the 20-day moving average, which settled at $2.03. In addition, Aclaris Therapeutics Inc saw 142.86% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACRS starting from Leonard Braden Michael, who purchase 206,025 shares at the price of $1.24 back on Aug 05 ’24. After this action, Leonard Braden Michael now owns 14,250,000 shares of Aclaris Therapeutics Inc, valued at $256,357 using the latest closing price.
Leonard Braden Michael, the 10% Owner of Aclaris Therapeutics Inc, purchase 167,544 shares at $1.29 during a trade that took place back on Aug 02 ’24, which means that Leonard Braden Michael is holding 14,043,975 shares at $216,400 based on the most recent closing price.
Stock Fundamentals for ACRS
Current profitability levels for the company are sitting at:
- -1.5 for the present operating margin
- 0.54 for the gross margin
The net margin for Aclaris Therapeutics Inc stands at -1.37. The total capital return value is set at -0.25. Equity return is now at value -25.83, with -18.47 for asset returns.
Currently, EBITDA for the company is -117.56 million with net debt to EBITDA at 0.76. When we switch over and look at the enterprise to sales, we see a ratio of 5.31. The receivables turnover for the company is 78.95for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.03.
Conclusion
In conclusion, Aclaris Therapeutics Inc (ACRS) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
